论文部分内容阅读
目的:探讨益肾通癃胶囊对良性前列腺增生(BPH)模型小鼠生殖激素水平的影响。方法:对SPF雄性小鼠皮下注射丙酸睾酮5mg/(kg·d),连续3周,待造模成功后分为6组:正常对照组,模型组,癃闭舒胶囊组,益肾通癃胶囊高、中、低剂量组,每组10只。益肾通癃胶囊高、中、低剂量组分别用1.2,0.6,0.3 g/kg益肾通癃胶囊混悬液灌胃,癃闭舒胶囊组用0.45 g/kg癃闭舒胶囊混悬液灌胃,正常对照组及模型组给予同体积蒸馏水。给药8周后处死小鼠,称取前列腺湿重并计算前列腺指数(PI),测量小鼠血清中睾酮(T)、雌二醇(E2)的水平、E2/T比值,光镜下观察小鼠前列腺组织的形态变化。结果:与模型组比较,益肾通癃胶囊中、高剂量组及癃闭舒胶囊组均可降低模型小鼠前列腺湿重、PI指数(P均<0.01)。各组小鼠血清T、E2、E2/T水平:正常对照组:(1.73±0.02)ng/ml、(73.08±1.03)pg/ml、42.30±0.53;模型组:(3.86±0.02)ng/ml,(145.79±0.88)pg/ml,37.76±0.25;癃闭舒胶囊组:(2.47±0.02)ng/ml,(95.87±0.47)pg/ml,38.80±0.13;益肾通癃胶囊高剂量组:(2.75±0.03)ng/ml,(107.11±0.61)pg/ml,38.92±0.36;益肾通癃胶囊中剂量组:(2.77±0.02)ng/ml,(112.16±0.82)pg/ml,40.56±0.29;益肾通癃胶囊低剂量组:(2.91±0.03)ng/ml,(112.68±0.77)pg/ml,38.80±0.42,各组与模型组相比,差异均具有统计学意义(P<0.05或P<0.01)。结论:益肾通癃胶囊可能通过降低BPH模型小鼠血清T、E2,升高E2/T比值,揭示了益肾通癃胶囊治疗BPH的机制。
Objective: To investigate the effect of Yishen Tongxuan capsule on reproductive hormone in benign prostatic hyperplasia (BPH) model mice. Methods: SPF male mice were injected subcutaneously with 5 mg / (kg · d) of testosterone for 3 weeks, and then divided into 6 groups: normal control group, model group, Yusuhu capsule group, Yishen Tong癃 Capsule high, medium and low dose group, 10 in each group. Yishen Tongliao Capsule high, medium and low dose groups were administered with 0.2,0.6,0.3 g / kg Yishen Tongzhu capsule suspension gavage, 癃 closed Shu capsule group with 0.45 g / kg 癃 closed capsules suspension Gavage, normal control group and model group were given the same volume of distilled water. The mice were sacrificed 8 weeks after the administration, the wet weight of the prostate was weighed and the Prostate Index (PI) was calculated. The levels of testosterone (T), estradiol (E2) and E2 / T were measured. Morphological changes of mouse prostate tissue. Results: Compared with the model group, the Yishen Tongxuan capsule, the high dose group and the Shuai Shutu capsule group could reduce the wet weight and PI of the model mice (all P <0.01). The levels of serum T, E2 and E2 / T in each group of mice were: normal control group: (1.73 ± 0.02) ng / ml, (73.08 ± 1.03) pg / ml and 42.30 ± 0.53; ml, (145.79 ± 0.88) pg / ml and 37.76 ± 0.25, respectively. The rats in Shufusu Capsule group were (2.47 ± 0.02) ng / ml, (95.87 ± 0.47) pg / ml and 38.80 ± 0.13, (2.75 ± 0.03) ng / ml, (107.11 ± 0.61) pg / ml and 38.92 ± 0.36, respectively. The dosage of YSJT capsule was (2.77 ± 0.02) ng / ml, (112.16 ± 0.82) pg / ml , 40.56 ± 0.29, respectively. The Yishen Tongxuan capsule low dose group was (2.91 ± 0.03) ng / ml, (112.68 ± 0.77) pg / ml and 38.80 ± 0.42 respectively. There was significant difference between each group and the model group (P <0.05 or P <0.01). CONCLUSION: YSKT capsule may reduce the level of serum T, E2 and increase the ratio of E2 / T in mice with BPH and reveal the mechanism of YSKT in the treatment of BPH.